Revance Therapeutics Inc (RVNC): Did you go with Josh? {Fruchter}..if so,...

Did you go with Josh? {Fruchter}..if so, I

stocksrising · 2025-01-09T22:32:01.6800000Z

Did you go with Josh? {Fruchter}..if so, I started to send docs but decided to just take the hit and move on ...good luck, we will all "win" something ( pennies perhaps) but will get more satisfaction for Fooley & Crew's loss !! GLTA

Play Episode

11min

Proactive - Interviews for investors

Immunic CMO discusses significance of MS Awareness Month; progress with treatment

Immunic Inc (NASDAQ:IMUX) chief medical officer Dr Andreas Muehler talked with Proactive's Stephen Gunnion about the company’s work in multiple sclerosis (MS) as MS Awareness Month concludes. Muehler discussed the importance of continued research funding and the community’s role in advancing treatment. He highlighted the company’s lead asset, vidofludimus calcium, which is in advanced-stage clinical trials. Results from the phase 2 EMPHASIS trial in relapsing-remitting MS showed a reduction of about three-quarters of new MRI lesions compared to placebo. Muehler said, “This is a very good value,” and pointed to biomarker data showing a strong, dose-linear suppression of neurofilament — a sign of nerve cell damage. A phase 3 program involving more than 2,000 patients is now underway, with data expected in 2026. In progressive MS, Immunic is close to reporting data from its phase 2 CALLIPER trial, having already seen positive biomarker signals at 24 weeks. Muehler addressed patients’ fears of disability, stressing the company’s commitment to tackling "progression independent of relapse activity (PIRA)", a key unmet need. He emphasized vidofludimus calcium’s dual mechanism — both anti-inflammatory and neuroprotective — and its potential to become the first oral drug targeting the full spectrum of MS. To hear more insights from Immunic and other biotech leaders, visit Proactive’s YouTube channel. Don’t forget to like the video, subscribe to the channel, and enable notifications for future content. #ImmunicTherapeutics #MultipleSclerosis #MSAwarenessMonth #vidofludimuscalcium #MSTreatment #ClinicalTrials #Neuroprotection #MSResearch #BiotechNews #ProgressiveMS #RelapsingMS #PIRA #DrugDevelopment

Proactive - Interviews for investors

Biome Australia expands global footprint, targets strong growth in clinically proven Probiotics

Biome Australia Managing Director Blair Norfolk joined Steve Darling from Proactive to talk about the company’s expansion strategy and continued growth in clinically validated, condition-specific probiotics. As a leader in live biotherapeutics, Biome Australia has developed probiotics with proven benefits across various health conditions, including mental health, asthma, cardiovascular health, and skin care. The company has over 20 clinical trials validating its products in those areas including the world’s first asthma probiotic, which achieved a 64% reduction in asthma events. Biome’s practitioner-only model ensures that products are recommended by health professionals and sold behind pharmacy counters, contributing to approximately 30% of total sales. While Australia remains the core market, generating over 90% of revenue, Biome is actively expanding into New Zealand, the UK, Ireland, and Canada. Norfolk noted that early results in Canada are ahead of schedule, with further updates expected on the ASX. Instead of launching new products, Biome is focused on expanding use cases for its existing 18-product portfolio, ensuring efficient cash flow management and lower product risk. Biome has emerged as the #2 probiotics brand in Australia’s community pharmacy market by total revenue. Norfolk credited ongoing research and innovation as key drivers of success. Looking ahead, Biome expects a strong close to FY25, fueled by increased demand during cold and flu season, and is on track to deliver its first full-year net profit as part of its Vision 27 strategic plan. #proactiveinvestors #biomeaustralialimited #asx #bio #BlairNorfolk #LiveBiotherapeutics #MentalHealthProbiotics #AsthmaTreatment #PharmaceuticalGrowth #ASXUpdates #NaturalMedicine #TargetedTherapy #PharmacyInnovation #InvestingInHealth #CanadianPharma #ColdAndFluSeason

Proactive - Interviews for investors

Itaconix CEO on 2025 strategy and profitability goals

Itaconix PLC (AIM:ITX, OTCQB:ITXXF) CEO John Shaw joined Steve Darling from Proactive to provide an update on the company’s progress following its strategic restructuring and to discuss what lies ahead for 2025. Shaw highlighted that the company ended 2024 with strong momentum, achieving nearly $3.7 million in revenue in the second half, marking one of its highest-ever earnings periods. The restructuring initiative focused on enhancing profitability, with a significant emphasis on reshaping the customer base. Shaw noted, “We actually increased our gross profit margin from about 31% to almost 35% last year.” Despite experiencing lower revenue in some areas, the company was able to maintain steady gross profits due to its emphasis on margin improvement. Shaw also discussed significant product developments, including the launch of Itaconix TSI 422, a new detergent ingredient that is gaining traction in North America and Europe. He further explained how the SPARX program, introduced in October, is helping accelerate customer collaboration in key product categories, positioning the company for continued growth. In addition to product development, the company has made strategic investments in its operations, marketing, and regulatory capabilities to support its growth trajectory. Shaw expressed confidence in the company’s production team and infrastructure, stating, “We really have everything in place we need right now to have a great run over the next 24 months.” While tariffs remain a consideration, Shaw believes any impacts will be manageable, and in some cases, could even be beneficial to the company. #proactiveinvestors #itaconixplc #aim #itx #otcqb #itxxf #SustainableChemicals #CleanTech #TSI422 #SPARXProgram #SpecialtyChemicals #JohnShaw #InvestorUpdates #ProactiveInvestors #GreenChemistry #DetergentInnovation #GrossProfitMargins #RestructuringSuccess

Proactive - Interviews for investors

2D Photonics CEO discusses plans to scale up advanced graphene-based photonics technology

Frontier IP Group portfolio company 2D Photonics CEO Ben Jensen talked with Proactive's Stephen Gunnion about the company’s recent €25 million funding round and its plans to scale up its advanced graphene-based photonics technology. Jensen explained the growing demand for faster, more cost-effective data transmission solutions, driven by sectors such as AI and 5G. “What’s required today is ever faster data transmission at lower costs,” he said. According to Jensen, the new device architecture 2D Photonics has developed simplifies photonics design while significantly improving performance. This innovation is crucial for enabling higher bandwidth and lower power consumption across data networks. The funding will support the expansion of the leadership team and the development of pilot production capabilities. Jensen emphasized the importance of execution at this early stage, noting that the goal is to demonstrate the scalability of the technology for semiconductor foundries and ultimately reach high-volume manufacturing. He also discussed future applications, pointing to sectors such as space and defence, where rugged environments make traditional photonics challenging. In addition, the technology has relevance for Advanced Driver-Assistance Systems (ADAS), where rapid data transmission between sensors is critical for vehicle safety. Visit Proactive’s YouTube channel for more insightful interviews like this. Don’t forget to like this video, subscribe to our channel, and enable notifications so you never miss an update. #GraphenePhotonics #2DPhotonics #FrontierIPGroup #DataTransmission #SemiconductorTech #ADAS #SpaceTech #PhotonicsInnovation #GrapheneTech #DeepTechStartups #HighSpeedData #BenJensen #ProactiveInvestors

Followers	7
Posts	681
Boards Moderated	0
Alias Born	06/08/2009

Volume:	-
Day Range:
Bid:	3.84
Ask:	3.10
Last Trade Time:
Total Trades:

Volume
Day Range:
Bid Price
Ask Price
Last Trade Time:

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

RVNC Detailed Quote

Recent RVNC News

More RVNC News

Boards:

Quotes:

Boards

News

Market Data

Markets

Discover

Discover

Boards:

Quotes:

Recent RVNC News

Go Ad-Free